Literature DB >> 30659072

Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes.

Daigo Saito1, Yoichi Oikawa2, Yuya Yano1, Yuichi Ikegami1, Atsushi Satomura1, Masashi Isshiki1, Susumu Kurihara1, Ikuo Inoue1, Mitsuhiko Noda1, Akira Shimada1.   

Abstract

Entities:  

Year:  2019        PMID： 30659072     DOI： 10.2337/dc18-1673

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

1.  Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.

Authors:  Kazuhisa Kusuki; Saya Suzuki; Yuzo Mizuno
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-04-29

2.  A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.

Authors:  Naoko Yamamoto; Yuya Tsurutani; Sho Katsuragawa; Haremaru Kubo; Takashi Sunouchi; Rei Hirose; Yoshitomo Hoshino; Masahiro Ichikawa; Tomoko Takiguchi; Hiroko Yukawa; Hitoshi Arioka; Jun Saitou; Tetsuo Nishikawa
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

3.  PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.

Authors:  Cuiping Lin; Xuan Li; Yu Qiu; Zheng Chen; Jianping Liu
Journal:  Front Public Health       Date:  2022-08-05

4.  Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.

Authors:  Masaaki Miyauchi; Masao Toyoda; Jie Zhang; Naoko Hamada; Takashi Yamawaki; Jun Tanaka; Kazuki Harada; Fumihiro Kashizaki; Masafumi Fukagawa
Journal:  J Diabetes Investig       Date:  2019-10-06       Impact factor: 4.232

5.  Serum 1,5-Anhydroglucitol to Glycated Albumin Ratio Can Help Early Distinguish Fulminant Type 1 Diabetes Mellitus from Newly Onset Type 1A Diabetes Mellitus.

Authors:  Lingwen Ying; Xiaojing Ma; Yun Shen; Jingyi Lu; Wei Lu; Wei Zhu; Yufei Wang; Yuqian Bao; Jian Zhou
Journal:  J Diabetes Res       Date:  2020-03-20       Impact factor: 4.011
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.